Skip to main content
HALEOS LABS LIMITED logo

HALEOS LABS LIMITED — Investor Relations & Filings

Ticker · HALEOSLABS ISIN · INE320X01016 LEI · 335800DGMSN4RZ5D8N90 BSE.NS Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2020-03-09 Regulatory Filings
Country IN India
Listing BSE.NS HALEOSLABS

About HALEOS LABS LIMITED

https://www.haleoslabs.com

Haleos Labs Limited is a technology-driven enterprise focused on providing comprehensive software development and information technology solutions. The company specializes in the design, development, and implementation of custom software applications, web-based platforms, and digital transformation strategies. Its core competencies include software engineering, system integration, and the maintenance of complex digital infrastructures. Haleos Labs Limited serves a diverse range of clients by delivering scalable technological frameworks and innovative research-led solutions aimed at optimizing operational efficiency and enhancing digital presence. The firm emphasizes technical excellence and the application of modern development methodologies to address evolving business requirements in the digital landscape.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document text contains only placeholders for images and no textual content or substantive information. The true document length is only 170 characters, which is extremely short and contains no report or announcement details. Given the lack of content, this cannot be classified as a report or detailed filing. It is most consistent with a Regulatory Filing (RNS) as a fallback category for miscellaneous or non-informative filings.
2020-03-09 English
Updates
Major Shareholding Notification Classification · 95% confidence The document is a detailed disclosure under SEBI regulations about the transfer of shares among promoter group members by way of gift. It includes specifics about the transaction date, parties involved, number of shares transferred, and percentage holdings before and after the transaction. The document references SEBI (Substantial Acquisitions and Takeovers) Regulations and SEBI (Prohibition of Insider Trading) Regulations, indicating it is a regulatory filing related to shareholding changes. It is not an annual report, earnings release, or management discussion. It is not a proxy or voting result announcement. The content fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels. The document is substantive and not merely an announcement or certification, so it is not RNS or RPA. Therefore, the correct classification is MRQ with high confidence.
2020-02-22 English
Updates
Regulatory Filings Classification · 95% confidence The document contains only references to omitted pictures and no textual content or financial data. It is extremely short (221 characters) and does not contain any report, announcement, or detailed information. Given the lack of content, it cannot be classified as a substantive report or announcement. It fits best as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings without meaningful content.
2020-02-17 English
Financial Result Updates
Regulatory Filings
2020-02-15 English
Change in Company Secretary/Compliance Officer
Board/Management Information Classification · 100% confidence The document is a formal announcement dated February 14, 2020, from SMS Lifesciences India Limited addressed to stock exchanges (BSE and NSE). It informs about the appointment of a new Company Secretary, Compliance Officer, and Key Managerial Personnel. The document includes the consent letter of the appointee, details under SEBI (Prohibition of Insider Trading) Regulations, and disclosures related to securities held by the appointee. There are no financial statements, earnings data, or detailed management discussion. The content is focused on management personnel change and regulatory compliance disclosures. Therefore, this document fits the category of Board/Management Information (MANG). The document length (9748 characters) and content confirm it is not a brief announcement or a report publication notice but a substantive management change filing.
2020-02-14 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 100% confidence The document is a communication from SMS Lifesciences India Limited to stock exchanges (BSE and NSE) dated February 14, 2020. It announces the outcome of a board meeting where the Board approved the standalone and consolidated unaudited financial results for the third quarter and nine months ended December 31, 2019, along with a Limited Review Report. The document includes detailed financial data for the quarter and nine months ended December 31, 2019, such as revenue, expenses, profit, and earnings per share. The presence of unaudited financial results for a quarter and nine months period, along with a limited review report, indicates this is a quarterly interim financial report. The document also mentions appointment of a company secretary, but the primary content is the financial results. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). The document length (15,000 characters) and detailed financial data confirm it is the report itself, not just an announcement or certification.
2020-02-14 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.